Related references
Note: Only part of the references are listed.Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
Darren K. McGuire et al.
JAMA CARDIOLOGY (2021)
Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Yi-Wen Yu et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction A Substudy of the Empire HF Randomized Clinical Trial
Massar Omar et al.
JAMA CARDIOLOGY (2021)
Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus The IDDIA Trial
Chi Young Shim et al.
CIRCULATION (2021)
Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study
Jonas Oldgren et al.
DIABETES OBESITY & METABOLISM (2021)
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease A protocol for systematic review and meta-analysis
Baisong Yu et al.
MEDICINE (2021)
Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
Muhammad Shahzeb Khan et al.
JACC-HEART FAILURE (2021)
Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies
Nazha Hamdani et al.
EUROPEAN HEART JOURNAL (2021)
Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials
Gailin Ye et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2021)
Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials
Daobo Li et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Epigenetic Therapies for Heart Failure: Current Insights and Future Potential
Claudio Napoli et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2021)
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
Matthew M. Y. Lee et al.
CIRCULATION (2021)
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
Jagdeep S. S. Singh et al.
DIABETES CARE (2020)
The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: TheCANA-HFstudy
Salvatore Carbone et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2020)
Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
Atsushi Tanaka et al.
ESC HEART FAILURE (2020)
Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus
Dimitrios Patoulias et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress
Jonathan J. H. Bray et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
Alexander J. M. Brown et al.
EUROPEAN HEART JOURNAL (2020)
Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus
Kentaro Ejiri et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial
Mie K. Eickhoff et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients - A Randomized Controlled Trial -
Hiroyuki Kayano et al.
CIRCULATION JOURNAL (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis
Javed Butler et al.
ESC HEART FAILURE (2020)
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors A State-of-the-Art Review
Gary D. Lopaschuk et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)
The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Hsiang-Chun Lee et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Unresolved issues in left ventricular postischemic remodeling and progression to heart failure
Edoardo Gronda et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2019)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction
Alberto Aimo et al.
JACC-HEART FAILURE (2019)
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
Qingmiao Shao et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload
Lin Shi et al.
AMERICAN JOURNAL OF HYPERTENSION (2019)
Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction
Kim A. Connelly et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Thomas A. Zelniker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction
Jasper Tromp et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling
Leonardo Schirone et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
Epigenetics in heart failure phenotypes
Alexander Berezin
BBA CLINICAL (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Luseogliflozin: First Global Approval
Anthony Markham et al.
DRUGS (2014)
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
Barry A. Borlaug et al.
EUROPEAN HEART JOURNAL (2011)
A systematic review identifies a lack of standardization in methods for handling missing variance data
N Wiebe et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2006)
Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling
JN Cohn et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
Share Paper
